Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Recruiting now · Phase 1
Conditions studied: AML, AML With Mutated NPM1, Hematologic Malignancy, KMT2Ar, NPM1 Mutation, MLL Rearrangement, Leukemia, Acute Myeloid Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Acute Leukemia, Neoplasms by Histologic Type
In brief
The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.
Key facts
- Study ID
- NCT06001788
- Run by
- Kura Oncology, Inc.
- People needed
- 171
- Starts
- 2024-02-22
- Expected to finish
- 2027-08-01
- Last updated by the study team
- 2026-04-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Hospital Universitari y Politecnic La Fe — Valencia, Spain (enrolling)
- USC Norris Comprehensive Cancer Center — Los Angeles, California, United States (enrolling)
- UCLA Health - Bowyer Oncology Center — Los Angeles, California, United States (enrolling)
- UC Irvine Health Chao Family Comprehensive Cancer Center — Orange, California, United States (enrolling)
- University of California San Francisco — San Francisco, California, United States (enrolling)
- Colorado Blood Cancer Institute — Denver, Colorado, United States (enrolling)
- Smilow Cancer Hospital at Yale New Haven — New Haven, Connecticut, United States (enrolling)
- Emory Healthcare - The Emory Clinic — Atlanta, Georgia, United States (enrolling)
- Georgia Cancer Center at Augusta University — Augusta, Georgia, United States (enrolling)
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University — Chicago, Illinois, United States (enrolling)
- Loyola University Medical Center — Maywood, Illinois, United States (enrolling)
- Hospital Universitario Virgen del Rocío — Seville, Spain (enrolling)
- Banner MD Anderson Cancer Center — Gilbert, Arizona, United States (enrolling)
- University of Iowa Hospitals & Clinics — Iowa City, Iowa, United States (enrolling)
- The University of Kansas Cancer Center — Kansas City, Kansas, United States (enrolling)
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States (enrolling)
- Karmanos Cancer Institute — Detroit, Michigan, United States (enrolling)
- Henry Ford Cancer Institute — Detroit, Michigan, United States (enrolling)
- Washington University School of Medicine — St Louis, Missouri, United States (enrolling)
- University of Nebraska Medical Center — Omaha, Nebraska, United States (enrolling)
- John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey, United States (enrolling)
- Roswell Park Comprehensive Cancer Center — Buffalo, New York, United States (enrolling)
- Northwell Health, LLC PRIME — Lake Success, New York, United States (enrolling)
- Memorial Sloan Kettering Cancer Center — New York, New York, United States (enrolling)
- Weill Cornell Medical College-NY Presbyterian Hospital — New York, New York, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.